menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Harmony Updates SNDA Status For Pitolisant In Idiopathic Hypersomnia

    BUSINESSWIRE

    HARMONY BIOSCIENCES Acknowledges FDA Action on WAKIX® Citizen Petition

    PR NEWSWIRE

    Harmony Receives FDA Approval For WAKIX® (Pitolisant) In Pediatric Narcolepsy

    PR NEWSWIRE

    Harmony Bio Initiates Ph 3 of Pitolisant in Patients with Prader-Willi Syndrome

    PR NEWSWIRE

    Harmony Biosciences Receives FDA Orphan Drug Designation For Pitolisant

    PR NEWSWIRE

    Harmony Announces Positive Data From Phase 2 Study Evaluating Pitolisant

    PR NEWSWIRE

    FDA Confirms Paragraph IV Patent Litigation for Pitolisant Hydrochloride Tablets

    FDA

    Harmony Bio Announces Topline Data From Phase 3 Study Evaluating Pitolisant

    PR NEWSWIRE

    Harmony Biosciences Announces FDA Orphan Drug Designation For Pitolisant

    PR NEWSWIRE

    HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS

    PR NEWSWIRE

    Harmony Bio Announces Plans To Initiate Piii Registrational Study Of Pitolisant

    PR NEWSWIRE

    China NMPA approves RareStone`s pitolisant for the treatment of narcolepsy

    PR NEWSWIRE

    Harmony Announces Positive Phase 2 Signal Detection Study Evaluating Pitolisant

    PR NEWSWIRE

    Bioprojet: WAKIX receives approval for the treatment of narcolepsy

    PR NEWSWIRE

    Harmony reports positive data from Phase II Prader-Willi syndrome trial

    CLINICALTRIALSARENA

    Harmony Biosciences Reports Second Quarter 2022 Financial

    PRESS RELEASE

    Harmony Biosciences Presents Post-Hoc Analysis Of Wakix Pivotal Data

    PRNEWSWIRE

    Harmony begins Phase III idiopathic hypersomnia treatment trial

    CLINICALTRIALSARENA

    EMA nod for excessive daytime sleepiness med Ozawade

    PHARMATIMES

    Harmony Biosciences Announces Inclusion Of WAKIX® (pitolisant)

    PRNEWSWIRE

    Bioprojet`s Ozawade (pitolisant) Receives Approval in Europe

    EMA

    Harmony Biosciences To Present WAKIX® (pitolisant) Efficacy and Safety

    PRNEWSWIRE

    Harmony Biosciences To Present WAKIX® (pitolisant) Efficacy and Safety Data

    PRNEWSWIRE

    Harmony Biosciences To Present WAKIX® (Pitolisant) Data At The 2021 AAN

    PRNESWIRE

    Harmony To Present WAKIX® (Pitolisant) Data At The 2021 AAN Annual Meeting

    PRNESWIRE

    FDA Approvals Roundup: Inmazeb, Wakix, Venclexta

    RAPS

    Harmony’s sleep disorder drug Wakix gets US label extension

    PHARMAPHORUM

    Harmony Biosciences Presents Efficacy And Safety Analyses For WAKIX®

    PRNEWSWIRE

    Harmony Biosciences To Present New Data For WAKIX® (pitolisant) At SLEEP 2020

    PRNEWSWIRE

    Harmony Biosciences To Present New Data For WAKIX® (pitolisant) At SLEEP 2020

    PRNEWSWIRE

    Pitolisant for Daytime Sleepiness in Patients Obstructive Sleep Apnea Who Refuse

    NCBI

    WAKIX® (pitolisant) Data From Harmony Biosciences Included on American Academy

    PRNEWSWIRE

    Ex-biotech chief pleads guilty in college admissions scandal, faces a 10-month prison stretch in plea deal

    ENDPTS

    Following FDA approval, Wakix will gain a small share in narcolepsy market

    BIOSPECTRUMASIA

    Harmony Biosciences scores first approval in narcolepsy med Wakix

    FIERCE PHARMA

    Harmony Biosciences Announces FDA Approval Of WAKIX® (Pitolisant)

    PR NEWSWIRE

    Harmony Biosciences Makes Headway on Narcolepsy Drug Involving Histamine

    BIOSPACE

    Pitolisant Receives FDA Breakthrough Therapy and Fast Track Designations

    RAREDR

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.